Multiparametric magnetic resonance imaging ultrasound-guided fusion biopsy during active surveillance: A single-centre study.
12-core template (standard) biopsy
Prostate cancer
active surveillance
multiparametric magnetic resonance imaging/ultrasound fusion biopsy
Journal
Arab journal of urology
ISSN: 2090-598X
Titre abrégé: Arab J Urol
Pays: United States
ID NLM: 101562480
Informations de publication
Date de publication:
17 Apr 2020
17 Apr 2020
Historique:
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
9
10
2020
Statut:
epublish
Résumé
To analyse the role of multiparametric magnetic resonance imaging (mpMRI) ultrasound (US)-guided fusion biopsy (FB) in patients with low-risk prostate cancer (PCa) under active surveillance (AS). Our retrospective study included 47 patients under AS who consecutively underwent both FB and standard biopsy (SB), from May 2015 until November 2017. We defined FB as a transrectal US-guided biopsy based on mpMRI. The primary endpoint was to assess the rate of concordance between FB and SB in terms of diagnostic yield, as well as the rate of Gleason Score upgrading/downgrading between the two techniques. Cohen's kappa coefficient (κ) was applied to test the concordance between FB and SB. The median (interquartile range [IQR]) follow-up was 20 (13-37) months. The median (IQR) number of cores taken was 13 (12-14) at SB and 4 (4-6) at FB. Overall, FB missed 12/47 (26%) PCa diagnoses compared to SB. There was concordance between SB and FB in 64% of the patients. The In our present study, FB showed no superiority over SB for the detection of PCa. On the contrary, FB had a high rate of missed PCa compared to SB. Further studies are required to ascertain the role of FB in AS. AS: active surveillance; FB: fusion biopsy; IL: index lesion; IQR: interquartile range; mpMRI: multiparametric MRI; (cs)PCa: (clinically significant) prostate cancer; PI-RADS: Prostate Imaging-Reporting and Data System; PRIAS: Prostate Cancer Research International Active Surveillance; ROI: region of interest; SB: standard biopsy.
Identifiants
pubmed: 33029423
doi: 10.1080/2090598X.2020.1749477
pii: 1749477
pmc: PMC7473102
doi:
Types de publication
Journal Article
Langues
eng
Pagination
142-147Informations de copyright
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the authors.
Références
Radiographics. 2011 May-Jun;31(3):677-703
pubmed: 21571651
Invest Radiol. 2014 Mar;49(3):165-72
pubmed: 24220253
Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663
pubmed: 31022301
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Eur Urol. 2016 Dec;70(6):954-960
pubmed: 27329565
JAMA Surg. 2019 Sep 1;154(9):811-818
pubmed: 31188412
Eur Urol. 2013 Apr;63(4):597-603
pubmed: 23159452
Eur Urol. 2015 Sep;68(3):438-50
pubmed: 25480312
Eur Urol Focus. 2018 Jan;4(1):68-74
pubmed: 28753764
Urology. 2017 Dec;110:134-139
pubmed: 28842208
J Clin Oncol. 2015 Jan 20;33(3):272-7
pubmed: 25512465
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Cancer. 2013 Sep 15;119(18):3359-66
pubmed: 23821585
Eur Urol. 2017 Aug;72(2):282-288
pubmed: 27574821
Clin Imaging. 2017 May - Jun;43:64-68
pubmed: 28196759
Urology. 2018 Feb;112:12-19
pubmed: 28962878
Eur Urol. 2017 Feb;71(2):174-180
pubmed: 27236496
Curr Opin Urol. 2014 Mar;24(2):155-61
pubmed: 24451092
J Urol. 2014 Aug;192(2):385-90
pubmed: 24512956
Eur Urol. 2016 Nov;70(5):846-853
pubmed: 26810346
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur Urol. 2015 Jul;68(1):8-19
pubmed: 25454618
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
Eur Urol. 2017 Aug;72(2):238-249
pubmed: 28318726